The Broad One Health Endectocide-based Malaria Intervention in Africa project (BOHEMIA) begins its mass drug administration (MDA) activities in Kenya’s Kwale County. The MDA in Kenya is being implemented by the KEMRI-Wellcome Trust Research Programme and led by co-principal investigators Dr Marta Maia and Dr Joseph Mwangang
BOHEMIA aims to evaluate the effectiveness of ivermectin as a novel and complementary strategy to reduce malaria transmission by reducing mosquito populations. The MDA in Kenya is the second trial being conducted as part of the study funded by Unitaid and led by the Barcelona Institute of Global Health (ISGlobal).
The continued successful use of bed nets to prevent malaria has resulted in enormous reductions in malaria cases. Bed nets remain the principal prevention method, however, mosquitoes are adapting and becoming resistant to insecticides. In addition, mosquitos have changed their behaviors to bite at times when people are not under their bed nets and are also feeding on animals. This has resulted in the need for scientists to look for novel tools to complement bed nets in the fight against malaria.
Ivermectin is a drug, commonly used to treat parasitic infections like river blindness and head lice among others. It is known that if a mosquito bites a human who has been treated with ivermectin, it does not survive for long and may not be able to spread malaria. “Administering ivermectin to as many people as possible at the same time in a community might be a new way to control malaria transmission. With BOHEMIA, we are trying to generate evidence for this strategy,” says Dr Maia.
The trial will assess the safety of using ivermectin, and the efficacy of this novel vector control strategy to reduce malaria transmission. The drug will be administered to around 32,000 participants, in selected areas of Msambweni and Lungalunga sub-counties in Kwale county. The study area has been divided into clusters and these have been randomly assigned to two arms, with one arm receiving ivermectin, the trial drug, and the control group receiving albendazol.
Comments